Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells Corrigendum in /10.3892/ijo.2015.2954

Koido,Shigeo; Homma,Sadamu; Kan,Shin; Takakura,Kazuki; Namiki,Yoshihisa; Kobayashi,Hiroko; Ito,Zensho; Uchiyama,Kan; Kajihara,Mikio; Arihiro,Seiji; Arakawa,Hiroshi; Okamoto,Masato; Ohkusa,Toshifumi; Gong,Jianlin; Tajiri,Hisao

doi:10.3892/ijo.2014.2433

Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells

Corrigendum in: /10.3892/ijo.2015.2954

Authors:
- Shigeo Koido
- Sadamu Homma
- Shin Kan
- Kazuki Takakura
- Yoshihisa Namiki
- Hiroko Kobayashi
- Zensho Ito
- Kan Uchiyama
- Mikio Kajihara
- Seiji Arihiro
- Hiroshi Arakawa
- Masato Okamoto
- Toshifumi Ohkusa
- Jianlin Gong
- Hisao Tajiri
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Chiba 277-8564, Japan, Department of Oncology, Jikei University School of Medicine, Tokyo 105-8461, Japan, Institute of Clinical Medicine and Research, Jikei University School of Medicine, Chiba 277-8564, Japan, Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Published online on: May 9, 2014 https://doi.org/10.3892/ijo.2014.2433
Pages: 470-478

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous work has demonstrated that fusion cells generated from autologous monocyte-derived dendritic cells (MoDCs) and whole tumor cells induce efficient antigen-specific cytotoxic T lymphocytes. A major limitation to the use of this strategy is the availability of adequate amounts of autologous tumor cells. Moreover, MoDCs from cancer patients are often defective in their antigen-processing and presentation machinery. In this study, two types of allogeneic cells, a leukemia plasmacytoid dendritic cell (pDC) line (PMDC05) and pancreatic cancer cell lines (PANC-1 or MIA PaCa-2), were fused instead of autologous MoDCs and tumor cells. We created four types of pDC/tumor fusion cells by alternating fusion partners and treating with lipopolysaccharide (LPS): i) PMDC05 fused with PANC-1 (pDC/PANC-1), ii) PMDC05 fused with MIA PaCa-2 (pDC/MIA PaCa-2), iii) LPS-stimulated pDC/PANC-1 (LPS-pDC/PANC-1) and iv) LPS-stimulated pDC/MIA PaCa-2 (LPS-pDC/MIA PaCa-2) and examined their antitumor immune responses. The LPS-pDC/tumor cell fusions were the most active, as demonstrated by their: i) upregulated expression of HLA-DR and CD86 on a per-fusion-cell basis, ii) increased production of IL-12p70, iii) generation of a higher percentage of IFN-γ-producing CD4+ and CD8+ T cells and iv) augmented induction of MUC1-specific CD8+ T cells that lyse target tumor cells. This study provides the first evidence for an in vitro induction of antigen-specific cytotoxic T lymphocytes by LPS-stimulated fusion cells generated from leukemia plasmacytoid DCs and tumor cells and suggests that this strategy has potential applicability to the field of adoptive immunotherapy.

View Figures

View References

1.	Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991. View Article : Google Scholar : PubMed/NCBI
2.	Gong J, Chen D, Kashiwaba M and Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 3:558–561. 1997. View Article : Google Scholar : PubMed/NCBI
3.	Gong J, Koido S and Calderwood SK: Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines. 7:1055–1068. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Koido S, Homma S, Okamoto M, et al: Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology. 2:e244372013. View Article : Google Scholar : PubMed/NCBI
5.	Yanagimoto H, Takai S, Satoi S, et al: Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol. 114:52–60. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Colonna M, Trinchieri G and Liu YJ: Plasmacytoid dendritic cells in immunity. Nat Immunol. 5:1219–1226. 2004. View Article : Google Scholar
7.	Liu YJ: IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 23:275–306. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Kim R, Emi M, Tanabe K and Arihiro K: Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology. 121:149–157. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Segura E, Kapp E, Gupta N, et al: Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. Mol Immunol. 47:1765–1773. 2010. View Article : Google Scholar
10.	Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G and Leclerc C: Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood. 112:3713–3722. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Narita M, Watanabe N, Yamahira A, et al: A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 33:1224–1232. 2009. View Article : Google Scholar
12.	Watanabe N, Narita M, Yamahira A, et al: Transformation of dendritic cells from plasmacytoid to myeloid in a leukemic plasmacytoid dendritic cell line (PMDC05). Leuk Res. 34:1517–1524. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Yamahira A, Narita M, Nakamura T, et al: Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells. Leuk Res. 35:793–799. 2011. View Article : Google Scholar
14.	Yamahira A, Narita M, Ishii K, et al: Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene. Leuk Res. 36:1541–1546. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Koido S, Hara E, Homma S, et al: Dendritic/pancreatic carcinoma fusions for clinical use: comparative functional analysis of healthy-versus patient-derived fusions. Clin Immunol. 135:384–400. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Koido S and Gong J: Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines. Anticancer Res. 33:347–354. 2013.PubMed/NCBI
17.	Liu L, Chahroudi A, Silvestri G, et al: Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med. 8:185–189. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Lapteva N, Seethammagari MR, Hanks BA, et al: Enhanced activ ation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 67:10528–10537. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Luger R, Valookaran S, Knapp N, Vizzardelli C, Dohnal AM and Felzmann T: Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode. PLoS One. 8:e548792013. View Article : Google Scholar : PubMed/NCBI
20.	Koido S, Homma S, Okamoto M, et al: Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One. 8:e592802013. View Article : Google Scholar : PubMed/NCBI
21.	Kimura T and Finn OJ: MUC1 immunotherapy is here to stay. Expert Opin Biol Ther. 13:35–49. 2013. View Article : Google Scholar : PubMed/NCBI
22.	Brugger W, Buhring HJ, Grunebach F, et al: Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol. 17:1535–1544. 1999.PubMed/NCBI
23.	Wykes M, MacDonald KP, Tran M, et al: MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukoc Biol. 72:692–701. 2002.PubMed/NCBI
24.	Koido S, Hara E, Homma S, et al: Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol. 178:613–622. 2007. View Article : Google Scholar
25.	Koido S, Hara E, Homma S, et al: Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res. 11:7891–7900. 2005. View Article : Google Scholar
26.	Koido S, Hara E, Homma S, Ohkusa T, Gong J and Tajiri H: Cancer immunotherapy by fusions of dendritic cells and tumor cells. Immunotherapy. 1:49–62. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Haenssle HA, Krause SW, Emmert S, et al: Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother. 27:147–155. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Trefzer U, Herberth G, Wohlan K, et al: Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine. 23:2367–2373. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Lundqvist A, Palmborg A, Bidla G, Whelan M, Pandha H and Pisa P: Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol. 21:155–165. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Matsumoto S, Saito H, Tsujitani S and Ikeguchi M: Allogeneic gastric cancer cell-dendritic cell hybrids induce tumor antigen (carcinoembryonic antigen) specific CD8(+) T cells. Cancer Immunol Immunother. 55:131–139. 2006.PubMed/NCBI
31.	Marten A, Renoth S, Heinicke T, et al: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 14:483–494. 2003. View Article : Google Scholar
32.	Siders WM, Garron C, Shields J and Kaplan JM: Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells. Clin Transl Sci. 2:75–79. 2009. View Article : Google Scholar : PubMed/NCBI